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The gastrointestinal (GI) tract is separated from the body’s internal environment by a single
layer of epithelial cells, through which nutrients must pass for their absorption into the
bloodstream. Besides food and drink, the GI lumen is also exposed to bioactive chemicals
and bacterial products including short-chain fatty acids (SCFAs).Therefore, the GI tract has
to monitor the composition of its contents continuously to discriminate between neces-
sary and unnecessary compounds. Recent molecular identification of epithelial membrane
receptor proteins has revealed the sensory roles of intestinal epithelial cells in the gut
chemosensory system. Malfunctioning of these receptors may be responsible for a variety
of metabolic dysfunctions associated with obesity and related disorders. Recent studies
suggest that SCFAs produced by microbiota fermentation act as signaling molecules and
influence the host’s metabolism; uncovering the sensory mechanisms of such bacterial
metabolites would help us understand the interactions between the host and microbiota
in host energy homeostasis. In this review, the contribution of colonic SCFA receptors in
energy metabolism and our recent findings concerning the possible link between SCFA
receptors and host energy homeostasis are discussed.
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INTRODUCTION
Part of the gastrointestinal (GI) tract, the intestinal lumen is one-
way tube where food materials from the external environment are
progressively converted into molecular products. Approximately
100 trillion bacteria, which are termed the gut microbiota, are
present in the intestinal lumen, especially in the colon. A single
layer of epithelial cells separates this diverse bacterial community
from the internal environment. Thus, host–microbiota interac-
tions occur at the mucosal surface of the intestine. The genome of
the gut microbiota contains an estimated 150 times as many genes
as in the host genome, and continuously produces large amount
of various chemicals, including short-chain fatty acids (SCFAs),
which can be beneficial or harmful to the host (1). The intestinal
lumen is therefore continuously exposed to a multitude of dietary
antigens, microorganisms, and bacterial products.
It has become clear that the GI tract responds to a large array of
signals in the lumen including nutrient and non-nutrient chemi-
cals. As mentioned above, these responses occur at the level of the
mucosa, which contains the epithelial cells. The recent molecular
identification of membrane receptor proteins has revealed sensory
roles for these epithelial cells in the gut chemosensory system. The
failure of functional interactions within the gut chemosensory
system between the host and microbiota may cause a spectrum of
diseases beyond local GI disorders, such as obesity, diabetes, meta-
bolic syndrome, and various neurological diseases (2). Despite the
significant role of the gut microbiota in host health, the elucida-
tion of the molecular mechanistic pathways involved has not been
moving forward as expected.
SCFA RECEPTORS, FFA2 AND FFA3 IN THE COLON
Generally, the main functions of the colon are absorption of water
and electrolytes and storage of fecal matter before expulsion.
Most studies of the chemosensory system in the GI tract con-
cern the small intestine in relation to nutrient absorption, incretin
release, short-term energy control, appetite, satiety, and postpran-
dial glycemic control (3). As a result, for many years chemical
sensing in the colon has been considered less important compared
with that in the small intestine. However, recent studies suggest
that products of microbial metabolisms in the gut act as signaling
molecules and influence host energy homeostasis (4).
The gut epithelium is composed of different cell types. In
the colon, epithelial cells form a sheet consisting of absorptive
epithelial, goblet, enteroendocrine, M, and brush (tuft, caveo-
lae) cells (5) (Figure 1). Lamina propria cells and nerve fibers
lie close to the epithelial cells but do not directly contact the
lumen, and these act together with the cell sheet to monitor lumi-
nal contents. Among the epithelial cells, enteroendocrine cells
have been proposed to possess intestinal chemosensory func-
tion because of their open-type morphology with an apical brush
border surface that extends into the gut lumen that comes in con-
tact with chemical compounds (5). Individual enteroendocrine
cells are scattered throughout the mucosa, representing ~1%
of all epithelial cells in the intestine and comprise a solitary
chemosensory system (6). Enteroendocrine cells are subdivided
into more than 15–20 different cell types based on their major
secretory products and their location along the GI tract (5). A
recent study has also reported that certain enteroendocrine cells
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FIGURE 1 | Proposed model for roles of FFA2/FFA3 that might contribute
to host energy homeostasis. In non-ruminant mammals, short-chain fatty
acid (SCFA) is produced by microbiota in the distal small intestine and colon
from low-digestible carbohydrates, including resistant starch and soluble
oligo- and polysaccharides. These SCFAs are able to bind and activate FFA2
and/or FFA3 located on intestinal epithelia. This activation induces GLP-1 and
PYY release into the basolateral side. Released GLP-1 and PYY activate
enteric or primary afferent neurons in pelvic and vagal nerves in addition to
humoral pathways. These information travel to the CNS, then affect the host
metabolic rate to regulate energy homeostasis.
present in the GI tract express a variety of chemical receptors and
gustatory signaling elements such as α-gustducin, α-transducin,
and TRPM5 (7).
In 2003, FFA2 (GPR43) and FFA3 (GPR41) were deorpha-
nized as SCFA receptors (8–10). These two receptors share ~40%
amino acid sequence similarity and are conserved across several
mammalian species. They differ in affinity for SCFAs, tissue dis-
tribution, and physiological roles. FFA2 has a similar affinity for
acetate, propionate, and butyrate, while FFA3 has a more potent
affinity for propionate than butyrate and does not have a high
affinity for acetate. Thus, acetate preferentially activates FFA2, pro-
pionate mainly activates FFA3, and butyrate equally activates both
FFA2 and FFA3. FFA2 and FFA3 also have distinct G proteins cou-
pled in their intracellular signaling cascades; FFA2 couples both
pertussis toxin-sensitive (Gi/o) and toxin-insensitive (Gq) G pro-
teins, whereas FFA3 couples only to Gi/o protein. We hypothesized
that FFA2 and FFA3 function as molecular interfaces between the
gut microbiota and host colon. Indeed, SCFAs produced by bac-
terial fermentation in the colon affects local colonic functions;
luminal application of propionate and butyrate induces Cl− secre-
tion and muscle contraction in rat distal colons (11, 12). These
local effects are not induced by serosal application of SCFAs. Based
on these observations, SCFAs are likely to be detected by epithe-
lial cells through specific receptors. We made different antisera for
FFA2 and FFA3 using synthesized peptides to test this working
hypothesis (13).
Using RT-PCR and western blotting analysis, mRNA and pro-
tein for FFA2 were found in the distal ileum and colon in extracts
from separated rat mucosa as well as in human colon extracts
(13, 14). However, FFA2 mRNA was not detected in submucosal
or muscle layers in either species. FFA3 protein and mRNA were
detected in human colonic mucosa at higher expression levels than
in the submucosal or muscle layer (15). These results suggest the
existence of FFA2 and FFA3 in colonic mucosa.
Immunohistochemistry was used to identify the cellular dis-
tribution of FFA2 and FFA3 in the colon. FFA2-immunoreactive
epithelial cells were found in rat, guinea pig, and human colonic
epithelia, with particularly strong expression in PYY and GLP-
1-producing enteroendocrine L-cells but not 5-HT containing
enterochromaffin (EC) cells (13–16). Immunoreactivity for FFA2
in laboratory animals showed a similar pattern to that of the
human colon. FFA2-immunoreactive L-cells in the colon were
open-type with bodies extending to the luminal surface. FFA3
was also detected in human colonic open-type L-cells, but it is
unclear whether these two receptors are located in the same cells.
These morphological characteristics indicate that PYY- and GLP-
1-producing L-cells that express FFA2 and FFA3 are chemosensory
cells. Activation of these receptors by luminal SCFAs may trig-
ger PYY and/or GLP-1 release. Morphologically, it is still unclear
whether FFA2 or FFA3 confined to the apical or basolateral mem-
brane, although our physiological studies indicate that these recep-
tors are located on apical side (11, 12, 16). Further study is needed
to clarify the precise distribution pattern of FFA2 and FFA3 in
order to understand the physiological function of these receptors.
DIRECT EVIDENCE OF GLP-1 RELEASE FROM SCFAs
RECEPTOR EXPRESSING L-CELLS IN VITRO
The morphological data suggest that gut microbiota-derived
SCFAs in the colonic lumen function as stimuli for GLP-1 and PYY
release. SCFAs are known to trigger the release of gut hormones,
but results have been inconsistent due to differences in the systems
used. Enteroendocrine cell culture systems, such as murine STC-1
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(17), GLUTag (18), and human NCI-H716 cell lines (19) are often
used to study the effects of nutrients on the release gut hormones
in vitro. The results from single cell cultures, however, are diffi-
cult to extrapolate to understand receptor physiological function
because intestinal tissue contains different epithelial cell types as
well as the enteric nervous system and mucosal immune system,
which influence the secretion of gut hormones. In addition, even
in vivo experiments have inconsistent results; intravenous acetate
infusion in innervated and denervated loops in conscious pig did
not change the concentration of GLP-1 but did for PYY (20). On
the other hand, intravenous and rectal infusion of acetate raises
plasma PYY and GLP-1 in hyperinsulinemic human females (21).
There are a few possible reasons for such differences: (1) many
results of in vivo experiments are obtained from an infusion sys-
tem. This system cannot identify a precise stimulation or secretion
site, which is a disadvantage for elucidating the function of chem-
ical receptors in gut hormone secretion. (2) Most cultured cells in
in vitro cell culture system experiments cannot maintain cell polar-
ity. (3) Many studies cannot directly differentiate whether specific
gut hormone-containing enteroendocrine cells are activated to
secrete hormones through direct or indirect chemical sensing, par-
ticularly if non-enteroendocrine cells also express chemosensory
receptors. Indeed, our morphological data suggest that enterocytes
also express FFA2 and FFA3.
We used the Ussing chamber system to investigate whether
SCFA stimulation induces GLP-1 secretion and to define pre-
cise stimulation and secretion sites of FFAs. This preparation
maintains the polarity of epithelial cells and contains other cel-
lular elements like intact intestine. In addition, an advantage of
this system is that it allows simultaneous measurement of phys-
iological phenomena and hormone release. In muscle-stripped
mucosa–submucosal preparations, luminal application of 5 mM
propionate induced GLP-1 release into the basolateral side of the
rat distal colon (22). Simultaneously, 5 mM propionate induced
an increase in short-circuit current, which is a parameter of ion
transport in epithelial cells (22). These results show that SCFAs
promote GLP-1 secretion through FFAs. It is still unclear, which
type of receptor is involved in GLP-1 secretion, since both FFA2
and FFA3 are expressed in enteroendocrine L-cells containing PYY
and GLP-1 (13–15). From physiological studies, FFA3 might be
involved in this secretion process because acetate, which is the
preferable ligand of FFA2, had no effect on local physiological
responses including ion transport in the rat distal colon (22).
This is further supported by observations of mice lacking FFA2
or FFA3 that had reduced SCFA-triggered GLP-1 secretion in vitro
and in vivo conditions (23). Unfortunately, the molecular pathways
underlying the beneficial effects of SCFAs are still largely unknown.
Thus, further study is needed to identify molecular pathways of
FFA-stimulated GLP-1 secretion.
DIETARY FIBER SUPPLEMENTATION AFFECTS COLONIC
ENTEROENDOCRINE CELL POPULATIONS AND FFA
EXPRESSION IN THE COLON
Besides the direct effects of SCFAs on gut hormone release, some
studies have shown a relationship between dietary fiber intake – the
substrate for SCFA production by microbiota – and GI hormone
release. Indeed, non-digestible and fermentable dietary fibers, as
well as SCFAs themselves, have been shown to induce GLP-1
secretion in humans (24) and rodents (25), although the under-
lying mechanisms are poorly understood. On the other hand,
acute dietary fiber intake does not increase endogenous GLP-1
concentration in human subjects (26). To help elucidate these
mechanisms, long-term ingestion of fructooligosaccharide (FOS)
and its effects on density or expression patterns of FFA2, GLP-1,
and 5-HT in the colon were tested using rats. Dietary supple-
mentation with FOS for 4 weeks increased the number of L-cells
expressing GLP-1 approximately twofold in the rat proximal colon,
but did not affect fecal content or the density of EC cells producing
5-HT (27). These results suggest that luminal SCFAs selectively
induce the proliferation of GLP-1-producing cells. This is sup-
ported by the observation that long-term ingestion of fermentable
dietary fibers increases luminal concentration of SCFAs (28). FFA2
responding to supplementation with 5% FOS approximately dou-
bled in the proximal colon. This suggests that FFA2 plays a key
role in GLP-1 production and secretion in addition to FFA3. The
microflora environment in the gut must have time to adapt to a
new food source before the full effects of fermentation can take
effect; production of SCFAs usually requires a few days in animals
and humans. As a result, FOS has to be consumed during a long-
enough period to allow fermentation to occur and stimulate GLP-1
and PYY production. Therefore, continuous intake of fermentable
fiber in the diet is considered important for the expression of GLP-
1- and PYY-secreting L-cells in long-term energy homeostasis. As
colonic luminal SCFA concentrations are unlikely to be reduced
markedly in response to acute food ingestion, it is possible that
SCFAs produced by colonic bacterial fermentation provide chronic
stimulation to L-cells via FFA2 and FFA3 under physiological
condition.
The CNS plays an important role in the maintenance of body
weight and energy balance within a narrow range by regulat-
ing energy intake and expenditure. A reduction in body weight
requires long-term negative energy balance by reducing appetite
and food intake or by increasing energy expenditure, or both. GLP-
1 and PYY are postulated to be hormonal signals from the gut to the
brain to inhibit food intake and appetite control because reduced
food intake in part reflects increases in hormone release in con-
junction with decreased secretion of ghrelin, which increases food
intake through effects on hypothalamic, brainstem, and reward-
related circuitry (3). Released GLP-1 is rapidly degraded by DPP-4,
which results in a diminished concentration of GLP-1 in the
hepatoportal vein (~50%), and an even small amount entering
systemic circulation (<10%) (29). Thus, only a small amount of
GLP-1 has the chance to reach the CNS. A radiolabeled GLP-1 ana-
log has been shown to cross the blood–brain barrier by simple dif-
fusion in mice, and gut-derived GLP-1 may enter the brain through
the area postrema lacking blood–brain barrier (30). Therefore, an
alternative model of GLP-1 release from colonic L-cells should
be considered. For example, it is possible that continuous release
of GLP-1 affects CNS activity to modulate energy homeostasis
including appetite and satiety. Alternatively, FFA2/FFA3-activated
GLP-1 release from colonic L-cells may activate local gut signaling
events to activate the CNS through the pelvic nerve to modu-
late long-term regulation of appetite and satiety. However, further
physiological studies are needed to prove these hypotheses.
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GLP-1 is generally believed to be expressed mainly in a lim-
ited population of enteroendocrine cells in the ileum and the
colon (31). However, recent study suggests that enteroendocrine
cells have a much broader potential for expression than is gen-
erally believed (32). Furthermore, Li et al. (33) have shown that
there are many more L-cells expressing α-gustducin and GLP-1
in the colon than in the small intestine, and that cells express-
ing α-gustducin increase in distribution from nearly 0% in the
small intestine to ~29% in the colon (33), leading the authors to
postulate that colonic L-cells might histologically and functionally
differ from L-cells in the small intestine. These results suggest that
FFA2/FFA3-stimulated GLP-1 secretion from colonic L-cells has a
different physiological function than in the small intestine. GLP-1
release is suppressed in obese subjects, so the tonic stimulation of
GLP-1 secretion induced by FFAs may chronically affect systemic
energy homeostasis (34). Indeed, continuous GLP-1 receptor ago-
nist injection for 14 days has been shown to reduce body weight
(35). Therefore, the mode of action of GLP-1/PYY release in the
colon stimulated by FFA2 and FFA3 is considered different from
the mode of action in the small intestine. Stimulation and release
in the colon might be involved in long-term regulation of energy
homeostasis, while in the small intestine regulation occurs in the
short-term with appetite or feeding control.
CONCLUSION
Since obesity and metabolic disorders are associated with changes
in gut microbiota, the integral role of the gut microbiota in the reg-
ulation of host energy homeostasis is an important issue. SCFAs
are primary metabolites of gut bacteria and are present in the
colon at high concentrations. The SCFA receptors, FFA2 and
FFA3 are located in rodent and human colonic L-cells contain-
ing GLP-1 and PYY, whose release are involved in the regulation
of host energy homeostasis. Furthermore, luminal application of
SCFA induces GLP-1 secretion and long-term ingestion of FOS
influences the density of FFA2-expressing L-cells. Therefore, it
seems likely that the colonic epithelia communicate with the gut
microbiota through products and receptors to maintain long-term
host–bacterial interactions. The studies that aimed at elucidat-
ing physiological phenomena and underlying mechanisms in the
colon discussed in this review are important contributions in the
race to develop new therapeutic strategies for obesity and its related
disorders in future.
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